Home / News / Quick-Med expands global patent reach of Nimbus antimicrobial technology

Quick-Med expands global patent reach of Nimbus antimicrobial technology

19 Dec '12

3 min read

Quick-Med Technologies, Inc. a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced advances in patent coverage in India, China, and Canada for the Company's novel, non-leaching NIMBUS antimicrobial technology.

The State Intellectual Property of the People's Republic of China and the Patent Office of India have granted Quick-Med Technologies' pending patent entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers" in their respective jurisdictions. Additionally, the Canadian Intellectual Property Office has issued a "Notice of Allowance" for this pending patent in Canada. These new patents will significantly expand the international intellectual property coverage for NIMBUS.

The three new patents are similar to U.S. Patent No. 8,088,400, also entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers." They cover the Company's novel polyurethane-modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation that is built into the backbone of various polymers such as polyurethane in this case.

The new patents are key "composition-of-matter" patents that cover incorporation of a NIMBUS polycation into main chain of a urethane polymer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity. The patents provide protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.

"This patent adds an exciting new dimension to our NIMBUS technology," says Dr. William Toreki, co-inventor and Quick-Med's vice president of Research & Development. "Our new polyurethane polycation has been licensed for medical adhesives and is well suited for a wide range of applications including films and coatings, catheters and other types of extruded tubing, and as a durable hand sanitizer."

"These NIMBUS patents are strategically important because they significantly expand the global coverage for our proprietary NIMBUS technology into exciting and emerging markets," said Dr. Bernd Liesenfeld, Quick-Med's president. "NIMBUS technology can make an important contribution to infection prevention programs in each of these markets."

NIMBUS technology provides efficacy against a broad range of both Gram-positive and Gram-negative bacteria. NIMBUS antimicrobials are not depleted in use, maintain effectiveness even in the presence of large amounts of blood or body fluids, and by design, pose no risk of bacteria developing resistance.

NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is the only non-leaching antimicrobial technology available in wound dressings. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.

Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the healthcare and consumer markets.

Quick-Med Technologies